evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,679 questions · 1,720 findings · 335 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 192 · 11.2%GRADE not reported 75 · 4.4%Very low 526 · 30.6%Low 504 · 29.3%Moderate 305 · 17.7%High 118 · 6.9%

Intervention not reported

Overall survival (OS) · HER2‐positive early breast cancer patients

The intervention leads to lower overall survival (OS) (high certainty).

1 finding from 1 review

Intervention not reported

Disease free survival (DFS) · HER2‐positive early breast cancer patients

The intervention leads to lower disease free survival (DFS) (high certainty).

1 finding from 1 review

Intervention not reported

Congestive heart failure (CHF) · HER2‐positive early breast cancer patients

The intervention leads to higher congestive heart failure (CHF) (high certainty).

1 finding from 1 review

Intervention not reported

Left ventricular ejection fraction decline (LVEF) · HER2‐positive early breast cancer patients

The intervention probably leads to higher left ventricular ejection fraction decline (LVEF) (moderate certainty).

1 finding from 1 review

Intervention not reported

Brain metastasis as first site of relapse · HER2‐positive early breast cancer patients

The intervention may leads to higher brain metastasis as first site of relapse (low certainty).

1 finding from 1 review

Intervention not reported

Death within 5 years · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)

The intervention showed no clear difference in death within 5 years (moderate certainty).

1 finding from 1 review

Intervention not reported

Disease progression within 5 years · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)

The intervention probably leads to lower disease progression within 5 years (moderate certainty).

1 finding from 1 review

Intervention not reported

Haematological adverse events (grade 3 or 4) · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)

The intervention showed no clear difference in haematological adverse events (grade 3 or 4) (moderate certainty).

1 finding from 1 review

Intervention not reported

Gastrointestinal adverse events (grade 3 or 4) · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)

The intervention showed no clear difference in gastrointestinal adverse events (grade 3 or 4) (moderate certainty).

1 finding from 1 review

Intervention not reported

Genitourinary adverse events (grade 3 or 4) · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)

The intervention showed no clear difference in genitourinary adverse events (grade 3 or 4) (moderate certainty).

1 finding from 1 review

Hormonal therapy vs placebo or no intervention

Effect on later sexual function · symptomatic or early postmenopausal women1.
4 findings from 1 review
Show 1 more finding

Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy

Disease-free survival · patients with early breast cancer

Capecitabine‐containing regimens showed no clear difference in disease‐free survival (DFS)median compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).

1 finding from 1 review

Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy

DFS: hormone receptor‐positivemedian · patients with early breast cancer

Capecitabine‐containing regimens showed no clear difference in DFS: hormone receptor‐positivemedian compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).

1 finding from 1 review